Tags

Type your tag names separated by a space and hit enter

Exploring the Association between Statin Use and the Risk of Parkinson's Disease: A Meta-Analysis of Observational Studies.
Neuroepidemiology. 2017; 49(3-4):142-151.N

Abstract

BACKGROUND

Parkinson's disease (PD) is a progressive disorder of the central nervous system. The prevalence of PD varies considerably by age group; it has a higher prevalence in patients aged 60 years and more. Several studies have shown that statin, a cholesterol-lowering medication, reduces the risk of developing PD, but evidence for this is so far inconclusive. The objective of this study is to evaluate the association between statin use and the risk of developing PD.

METHODS

PubMed, EMBASE, and the bibliographies of articles were searched for studies published between January 1, 1990, and January 1, 2017, which reported on the association between statin use and PD. Articles were included if they (1) were published in English, (2) reported patients treated with statin, and the outcome of interest was PD, (3) provided OR/HR with 95% CI or sufficient information to calculate the 95% CI. All abstracts, full-text articles, and sources were reviewed, with duplicate data excluded. Summary relative risk (RRs) with 95% CI was pooled using a random-effects model. Subgroup and sensitivity analyses were also conducted.

RESULTS

We selected 16 out of 529 unique abstracts for full-text review using our selection criteria, and 13 out of these 16 studies, comprising 4,877,059 persons, met all of our inclusion criteria. The overall pooled RR of PD was 0.70 (95% CI 0.58-0.84) with significant heterogeneity between estimates (I2 = 93.41%, p = 0.000) for the random-effects model. In subgroup analysis, the greater decreased risk was found in studies from Asia (RR 0.62 95% CI 0.51-0.76), whereas a moderate reduction was observed in studies from North America (RR 0.69 95% CI 0.47-1.00), but less reduction was observed in studies from Europe (RR 0.86 95% CI 0.80-0.92). Also, long-term statin use, simvastatin, and atorvastatin showed a higher rate of reduction with significance heterogeneity.

CONCLUSION

Our results showed that statin use is significantly associated with a lower risk of developing PD. Physicians should consider statin drug therapy, monitor its outcomes, and empower their patients to improve their knowledge, therapeutic outcomes, and quality of life. However, preventive measures and their associated mechanisms must be further assessed and explored.

Authors+Show Affiliations

Tzu Chi University, Department of Microbiology and Immunology, Hualien, Taiwan.Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan.Master Program in Global Health and Development, College of Public Health, Taipei Medical University, Taipei, Taiwan.International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan.International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan.International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan.Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan.Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan. Chair, Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan.

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

29145202

Citation

Poly, Tahmina Nasrin, et al. "Exploring the Association Between Statin Use and the Risk of Parkinson's Disease: a Meta-Analysis of Observational Studies." Neuroepidemiology, vol. 49, no. 3-4, 2017, pp. 142-151.
Poly TN, Islam MM, Walther BA, et al. Exploring the Association between Statin Use and the Risk of Parkinson's Disease: A Meta-Analysis of Observational Studies. Neuroepidemiology. 2017;49(3-4):142-151.
Poly, T. N., Islam, M. M., Walther, B. A., Yang, H. C., Nguyen, P. A., Huang, C. W., Shabbir, S. A., & Li, Y. J. (2017). Exploring the Association between Statin Use and the Risk of Parkinson's Disease: A Meta-Analysis of Observational Studies. Neuroepidemiology, 49(3-4), 142-151. https://doi.org/10.1159/000480401
Poly TN, et al. Exploring the Association Between Statin Use and the Risk of Parkinson's Disease: a Meta-Analysis of Observational Studies. Neuroepidemiology. 2017;49(3-4):142-151. PubMed PMID: 29145202.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Exploring the Association between Statin Use and the Risk of Parkinson's Disease: A Meta-Analysis of Observational Studies. AU - Poly,Tahmina Nasrin, AU - Islam,Md Mohaimenul, AU - Walther,Bruno Andreas, AU - Yang,Hsuan-Chia, AU - Nguyen,Phung-Anh, AU - Huang,Chih-Wei, AU - Shabbir,Syed-Abdul, AU - Li,Yu-Chuan Jack, Y1 - 2017/11/16/ PY - 2017/06/20/received PY - 2017/08/17/accepted PY - 2017/11/18/pubmed PY - 2019/7/4/medline PY - 2017/11/18/entrez KW - Statins KW - Heterogeneity KW - Hypertension KW - Parkinson’s disease KW - Stroke SP - 142 EP - 151 JF - Neuroepidemiology JO - Neuroepidemiology VL - 49 IS - 3-4 N2 - BACKGROUND: Parkinson's disease (PD) is a progressive disorder of the central nervous system. The prevalence of PD varies considerably by age group; it has a higher prevalence in patients aged 60 years and more. Several studies have shown that statin, a cholesterol-lowering medication, reduces the risk of developing PD, but evidence for this is so far inconclusive. The objective of this study is to evaluate the association between statin use and the risk of developing PD. METHODS: PubMed, EMBASE, and the bibliographies of articles were searched for studies published between January 1, 1990, and January 1, 2017, which reported on the association between statin use and PD. Articles were included if they (1) were published in English, (2) reported patients treated with statin, and the outcome of interest was PD, (3) provided OR/HR with 95% CI or sufficient information to calculate the 95% CI. All abstracts, full-text articles, and sources were reviewed, with duplicate data excluded. Summary relative risk (RRs) with 95% CI was pooled using a random-effects model. Subgroup and sensitivity analyses were also conducted. RESULTS: We selected 16 out of 529 unique abstracts for full-text review using our selection criteria, and 13 out of these 16 studies, comprising 4,877,059 persons, met all of our inclusion criteria. The overall pooled RR of PD was 0.70 (95% CI 0.58-0.84) with significant heterogeneity between estimates (I2 = 93.41%, p = 0.000) for the random-effects model. In subgroup analysis, the greater decreased risk was found in studies from Asia (RR 0.62 95% CI 0.51-0.76), whereas a moderate reduction was observed in studies from North America (RR 0.69 95% CI 0.47-1.00), but less reduction was observed in studies from Europe (RR 0.86 95% CI 0.80-0.92). Also, long-term statin use, simvastatin, and atorvastatin showed a higher rate of reduction with significance heterogeneity. CONCLUSION: Our results showed that statin use is significantly associated with a lower risk of developing PD. Physicians should consider statin drug therapy, monitor its outcomes, and empower their patients to improve their knowledge, therapeutic outcomes, and quality of life. However, preventive measures and their associated mechanisms must be further assessed and explored. SN - 1423-0208 UR - https://www.unboundmedicine.com/medline/citation/29145202/Exploring_the_Association_between_Statin_Use_and_the_Risk_of_Parkinson's_Disease:_A_Meta_Analysis_of_Observational_Studies_ DB - PRIME DP - Unbound Medicine ER -